<DOC>
	<DOCNO>NCT00039000</DOCNO>
	<brief_summary>The primary goal study determine people metastatic melanoma receive Heat Shock Protein-Peptide Complex - 96 ( HSPPC-96 Oncophage ) surgery live long people may may surgery receive conventional chemotherapy include IL-2/DTIC . A second goal determine safety frequency side effect subject receive therapy HSPPC-96 .</brief_summary>
	<brief_title>Study Heat Shock Protein-Peptide Complex ( HSPPC-96 ) Versus IL-2/DTIC Stage IV Melanoma</brief_title>
	<detailed_description>Primary Objective : - To determine whether subject stage IV melanoma randomize HSPPC-96 longer survival subject randomize physician 's choice include interleukin-2 and/or dacarbazine/temozolomide and/or complete tumor resection . Secondary Objective : - To determine frequency adverse event subject randomize HSPPC-96 .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Eligibility Assessment : ( The follow assessment must obtain within three week prior randomization study ) Medical history physical examination ( include EGOG score , evidence immunosuppression ) ; CT/MRI chest , abdomen pelvis ; Clinical examination ; CT/MRI brain ; Complete Blood Count differential include platelet ; Electrolytes ( Na , Cl , K , HCO3 , Ca , Mg , PO4 ) ; Renal function test ( BUN creatinine ) ; Liver function test ( bilirubin , AST , ALT ) ; Serum pregnancy test woman childbearing potential . Stage IV Melanoma ( AJCC ) ; No prior therapy stage IV melanoma ; No prior therapy interleukin2 and/or dacarbazine/temozolomide within past 12 month prior study entry ; Candidate surgical resection some/all sit melanoma expect obtain great tan equal 7 gram viable cancer tissue ( aggregate ) , equivalent great equal 2 cm lesion CT/MRI clinical examination ; No brain metastases ; ECOG score 0 1 ; Adequate cardiac function ; Adequate hematopoietic , liver renal function ; Female subject childbearing potential must agree use contraception study Signed write informed consent . Mucosal ocular melanoma ; Other malignancy treat within last five year , except situ cervix carcinoma nonmelanoma skin cancer ; Primary secondary immunodeficiency , opinion investigator ( include immunosuppressive disease , use systemic corticosteroid immunosuppressive medication ) ; Prior splenectomy ; Uncontrolled infection serious medical illness ; Women pregnant breastfeeding ; Subjects participate study require administration investigational drug/biologic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Immunotherapy , Cancer , Melanoma , Skin Cancer , tumor</keyword>
</DOC>